e-learning
resources
Stockholm 2007
Monday 17.09.2007
Interstitial lung disease: diagnostic and therapeutic novelties
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Improvement of the clinical response to infiximab in refractory sarcoidosis by reducing the dose interval
G. Jonker, G. van Kan, E. Ten Hoor-de Groot, M. Drent (Eindhoven, Maastricht, Netherlands)
Source:
Annual Congress 2007 - Interstitial lung disease: diagnostic and therapeutic novelties
Session:
Interstitial lung disease: diagnostic and therapeutic novelties
Session type:
Oral Presentation
Number:
1570
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Jonker, G. van Kan, E. Ten Hoor-de Groot, M. Drent (Eindhoven, Maastricht, Netherlands). Improvement of the clinical response to infiximab in refractory sarcoidosis by reducing the dose interval. Eur Respir J 2007; 30: Suppl. 51, 1570
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
Source: Eur Respir J 2014; 44: 1296-1307
Year: 2014
Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis
Source: Eur Respir J 2014; 43: 602-609
Year: 2013
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial
Source: Eur Respir J 2008; 31: 1189-1196
Year: 2008
Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?
Source: Eur Respir J 2016; 48: 1242-1245
Year: 2016
The clinical value of intravenous pulse therapy in first retreatment pulmonary tuberculosis patients
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
Clinical benefits of ambroxol and millimeter wave therapy combination in sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 669s
Year: 2004
Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Therapy with low dose methotrexate plus diprospan in patient with recalcitrant recidivating sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 541s
Year: 2006
Long-term treatment with infliximab in patients with sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
Early treatment response may predict long-term mepolizumab benefit in severe asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Standard therapy for sarcoidosis
Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis
Year: 2005
Efficacy of traditional and combined therapy in patients with sarcoidosis
Source: Eur Respir J 2003; 22: Suppl. 45, 234s
Year: 2003
Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021
Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept